RxDoctor Payments Data

Lynzi Morgan, APRN

Nurse Practitioner · Pryor, OKNPI 1700545662

Payments from drug & device makers

$1,266in general payments, 2019–2025

Across 73 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$207
  • Lilly USA, LLC$172
  • Pfizer$141
  • Novo Nordisk$115
  • AstraZeneca$109
  • Amgen$106
  • plus $416 from 11 others

What the payments were for

  • Food & beverage$1,266100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,266 in reported general payments places this provider in the 80th percentile of 824 nurse practitioner providers in Oklahoma.

See all nurse practitioner providers in Oklahoma

Medicare billing

Part B allowed, 2024
$397
Medicare patients
11
Services billed
20

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide55$56,679
JardianceEmpagliflozin51$53,899
MounjaroTirzepatide41$43,476
TrulicityDulaglutide32$33,310
CreonLipase/Protease/Amylase13$30,555
Breztri AerosphereBudesonide/Glycopyr/Formoterol28$22,880
FarxigaDapagliflozin Propanediol22$20,095
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$16,413
EliquisApixaban19$14,666
QuliptaAtogepant12$12,328
MyrbetriqMirabegron22$11,298
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$9,672
LinzessLinaclotide12$8,682
Tresiba Flextouch U-200Insulin Degludec11$7,979
SymbicortBudesonide/Formoterol Fumarate12$3,324

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$172$76,78773 claims
Novo NordiskOzempic$115$56,67955 claims
Boehringer IngelheimJardiance$53$53,89951 claims
AbbVieCreon, Qulipta, Linzess$207$51,56537 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$109$46,29862 claims
GSKTrelegy Ellipta$36$16,41323 claims
PfizerEliquis$141$14,66619 claims
Astellas Pharma US IncMyrbetriq$14$11,29822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 824 nurse practitioner providers in Oklahoma.

Other nurse practitioner in Pryor

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →